Helix BioPharma Corporation
Organization
Trials
L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer
Phase 1/2, Terminated, 28 people, Dec 18, 2019
Phase 2, Terminated, 9 people, Mar 26, 2019
Sources: clinicaltrials.gov
Organization
L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer
Phase 1/2, Terminated, 28 people, Dec 18, 2019
Phase 2, Terminated, 9 people, Mar 26, 2019
Sources: clinicaltrials.gov